vs
C4 Therapeutics, Inc.（CCCC）与Rocky Mountain Chocolate Factory, Inc.（RMCF）财务数据对比。点击上方公司名可切换其他公司
C4 Therapeutics, Inc.的季度营收约是Rocky Mountain Chocolate Factory, Inc.的1.5倍（$11.0M vs $7.5M），Rocky Mountain Chocolate Factory, Inc.净利率更高（-2.1% vs -186.0%，领先183.9%），C4 Therapeutics, Inc.同比增速更快（112.8% vs -4.4%），过去两年C4 Therapeutics, Inc.的营收复合增速更高（90.4% vs 1.9%）
C4 Therapeutics是一家临床阶段生物制药企业，专注于开发靶向蛋白降解疗法，用于治疗癌症及其他存在重大未满足医疗需求的严重疾病。公司依托自有专利TORPEDO平台设计小分子降解剂清除致病蛋白，目前拥有多条肿瘤领域研发管线，并与头部制药企业达成战略合作。
落基山巧克力厂是美国知名巧克力企业，同时开展国际特许经营业务，集糖果生产与零售运营于一体，总部位于美国科罗拉多州杜兰戈，除美国本土门店外，在巴拿马、菲律宾也设有经营网点。
CCCC vs RMCF — 直观对比
营收规模更大
CCCC
是对方的1.5倍
$7.5M
营收增速更快
CCCC
高出117.2%
-4.4%
净利率更高
RMCF
高出183.9%
-186.0%
两年增速更快
CCCC
近两年复合增速
1.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $7.5M |
| 净利润 | $-20.5M | $-155.0K |
| 毛利率 | — | 34.0% |
| 营业利润率 | -210.1% | 1.1% |
| 净利率 | -186.0% | -2.1% |
| 营收同比 | 112.8% | -4.4% |
| 净利润同比 | 40.7% | 81.7% |
| 每股收益（稀释后） | $-0.09 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCCCRMCF
| Q4 25 | $11.0M | $7.5M | ||
| Q3 25 | $11.2M | $6.8M | ||
| Q2 25 | $6.5M | $6.4M | ||
| Q1 25 | $7.2M | $8.9M | ||
| Q4 24 | $5.2M | $7.9M | ||
| Q3 24 | $15.4M | $6.4M | ||
| Q2 24 | $12.0M | $6.4M | ||
| Q1 24 | $3.0M | $7.3M |
净利润CCCCRMCF
| Q4 25 | $-20.5M | $-155.0K | ||
| Q3 25 | $-32.2M | $-662.0K | ||
| Q2 25 | $-26.0M | $-324.0K | ||
| Q1 25 | $-26.3M | $-2.9M | ||
| Q4 24 | $-34.6M | $-847.0K | ||
| Q3 24 | $-24.7M | $-722.0K | ||
| Q2 24 | $-17.7M | $-1.7M | ||
| Q1 24 | $-28.4M | $-1.6M |
毛利率CCCCRMCF
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 31.1% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | — | 31.8% | ||
| Q2 24 | — | 12.8% | ||
| Q1 24 | — | 24.3% |
营业利润率CCCCRMCF
| Q4 25 | -210.1% | 1.1% | ||
| Q3 25 | -306.4% | -7.0% | ||
| Q2 25 | -441.0% | -2.3% | ||
| Q1 25 | -402.9% | -30.3% | ||
| Q4 24 | -728.4% | -8.9% | ||
| Q3 24 | -183.9% | -14.3% | ||
| Q2 24 | -178.6% | -25.4% | ||
| Q1 24 | -1060.2% | -21.7% |
净利率CCCCRMCF
| Q4 25 | -186.0% | -2.1% | ||
| Q3 25 | -286.4% | -9.7% | ||
| Q2 25 | -402.6% | -5.1% | ||
| Q1 25 | -363.7% | -32.5% | ||
| Q4 24 | -667.8% | -10.7% | ||
| Q3 24 | -160.6% | -11.3% | ||
| Q2 24 | -147.6% | -25.9% | ||
| Q1 24 | -933.2% | -21.9% |
每股收益（稀释后）CCCCRMCF
| Q4 25 | $-0.09 | $-0.02 | ||
| Q3 25 | $-0.44 | $-0.09 | ||
| Q2 25 | $-0.37 | $-0.04 | ||
| Q1 25 | $-0.37 | $-0.38 | ||
| Q4 24 | $-0.50 | $-0.11 | ||
| Q3 24 | $-0.35 | $-0.11 | ||
| Q2 24 | $-0.26 | $-0.26 | ||
| Q1 24 | $-0.41 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $641.0K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $256.6M | $6.0M |
| 总资产 | $359.1M | $20.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCCCRMCF
| Q4 25 | $74.6M | $641.0K | ||
| Q3 25 | $58.8M | $2.0M | ||
| Q2 25 | $78.2M | $893.0K | ||
| Q1 25 | $51.3M | $720.0K | ||
| Q4 24 | $55.5M | $1.1M | ||
| Q3 24 | $59.6M | $973.0K | ||
| Q2 24 | $73.1M | $637.0K | ||
| Q1 24 | $89.7M | $2.1M |
股东权益CCCCRMCF
| Q4 25 | $256.6M | $6.0M | ||
| Q3 25 | $154.4M | $6.1M | ||
| Q2 25 | $174.1M | $6.7M | ||
| Q1 25 | $195.1M | $7.0M | ||
| Q4 24 | $216.0M | $9.8M | ||
| Q3 24 | $242.7M | $10.5M | ||
| Q2 24 | $247.1M | $9.0M | ||
| Q1 24 | $258.3M | $10.6M |
总资产CCCCRMCF
| Q4 25 | $359.1M | $20.7M | ||
| Q3 25 | $265.5M | $22.3M | ||
| Q2 25 | $296.5M | $20.1M | ||
| Q1 25 | $319.5M | $21.2M | ||
| Q4 24 | $349.6M | $21.6M | ||
| Q3 24 | $376.1M | $21.1M | ||
| Q2 24 | $381.1M | $19.0M | ||
| Q1 24 | $398.4M | $20.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.1M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-1.3M |
| 自由现金流率自由现金流/营收 | — | -16.9% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CCCCRMCF
| Q4 25 | $-22.1M | $-1.2M | ||
| Q3 25 | $-31.2M | $-488.0K | ||
| Q2 25 | $-12.1M | $350.0K | ||
| Q1 25 | $-33.3M | $1.2M | ||
| Q4 24 | $-17.9M | $-2.1M | ||
| Q3 24 | $-24.1M | $-3.5M | ||
| Q2 24 | $-5.0M | $-2.2M | ||
| Q1 24 | $-18.1M | $129.0K |
自由现金流CCCCRMCF
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $-31.6M | $-544.0K | ||
| Q2 25 | — | $182.0K | ||
| Q1 25 | — | — | ||
| Q4 24 | $-17.9M | — | ||
| Q3 24 | $-24.1M | $-4.6M | ||
| Q2 24 | $-5.2M | $-2.6M | ||
| Q1 24 | — | $-352.3K |
自由现金流率CCCCRMCF
| Q4 25 | — | -16.9% | ||
| Q3 25 | -281.5% | -8.0% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | -346.5% | — | ||
| Q3 24 | -157.2% | -72.6% | ||
| Q2 24 | -43.1% | -40.2% | ||
| Q1 24 | — | -4.9% |
资本支出强度CCCCRMCF
| Q4 25 | — | 0.5% | ||
| Q3 25 | 3.7% | 0.8% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.1% | 17.5% | ||
| Q2 24 | 1.6% | 6.5% | ||
| Q1 24 | 0.0% | 6.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCCC
暂无分部数据
RMCF
| Manufacturing | $5.9M | 78% |
| Transferred At Point In Time | $1.2M | 16% |
| Other | $414.0K | 5% |
